Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stop-and-go versus continuation nivolumab + ipilimumab after induction in PD-L1-positive metastatic NSCLC
2017-002540-33Phase 3Active
- Sponsor
- IFCT
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Continuation nivolumab + ipilimumab with Observation / stop-and-go (2 arms). Primary endpoint: Progression-free survival. Started Dec 2017; status: active.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-002540-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002540-33.